ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases

MLA

Carlomagno F, et al. “ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases.” Cancer Research, vol. 62, no. 24, Dec. 2002. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....24c6e8286301f2fb4608fb81f99f9252&authtype=sso&custid=ns315887.

APA

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Aj, R., Gabriella Fontanini, Fusco A, & Santoro M. (2002). ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research, 62(24).

Chicago

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan Aj, Gabriella Fontanini, Fusco A, and Santoro M. 2002. “ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases.” Cancer Research 62 (24). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid.dedup....24c6e8286301f2fb4608fb81f99f9252&authtype=sso&custid=ns315887.